High-Quality STROMUSC Boldane(Boldenolone Undecylenate)600mg/ml For Bodybuilding CAS:13103-34-9

    Boldenone Undecylenate: A Comprehensive Pharmacological and Clinical Overview

    Boldenone undecylenate represents one of the more structurally intriguing compounds within the broader family of anabolic-androgenic steroids (AAS). Originally synthesized for veterinary applications rather than human medicine, this substance has garnered substantial attention in athletic and physique-oriented communities over the past several decades. Understanding its chemical architecture, pharmacodynamic behavior, and clinical profile requires moving beyond gym folklore and examining the compound through a lens of pharmacology, endocrinology, and toxicology.

    At its core, boldenone undecylenate is the undecylenate esterified variant of boldenone, which itself is a derivative of testosterone. The structural modification occurs at the C1 and C2 positions, where a double bond is inserted-specifically, boldenone is 1-dehydrotestosterone. This seemingly minor alteration fundamentally changes the compound's androgenic-to-anabolic ratio compared to its parent hormone. The undecylenate ester attached at the 17-beta hydroxyl group serves not as an active pharmacophore but rather as a delivery mechanism, dramatically slowing the release of the active hormone from the injection site into systemic circulation.

    The undecylenate ester is notably longer than many other esterifications used in steroid chemistry-longer than enanthate, cypionate, and even decanoate in terms of carbon chain length. This particular esterification was selected during the compound's development to create an extremely prolonged release pattern, making it suitable for veterinary administration protocols where frequent dosing is impractical. The 600mg/ml concentration referenced in various underground preparations represents a supersaturated formulation significantly exceeding the concentration of pharmaceutical-grade veterinary products, which typically contain 25-50mg/ml or similar concentrations. Such high-concentration preparations raise concerns regarding sterility, pyrogenicity, and injection site reactions.

    Boldenone undecylenate first emerged from pharmaceutical research in the 1960s, with Squibb introducing it under the trade name Equipoise for veterinary use-specifically for horses. Its approved indications centered on improving the general condition and appetite in debilitated animals, as well as supporting weight gain in horses. Notably, it was never approved for human consumption in the United States or most other jurisdictions, remaining strictly within the domain of veterinary medicine.

    The compound's veterinary origins explain several of its pharmacological characteristics. Horses metabolize and distribute lipophilic compounds differently than humans, and formulations were optimized for intramuscular injection in large animals with substantial muscle mass. The translation of these veterinary parameters to human physiology involves considerable extrapolation and carries inherent risks.

    The pharmacological activity of boldenone undecylenate stems from its conversion to boldenone in vivo after ester hydrolysis. Once liberated, boldenone functions as an agonist at androgen receptors, initiating the canonical genomic pathway of androgen signaling. The 1-dehydro modification reduces the compound's affinity for 5-alpha reductase, meaning it does not convert as readily to dihydroboldenone as testosterone converts to dihydrotestosterone. This metabolic resistance alters its tissue-specific activity profile.

    Boldenone demonstrates moderate anabolic properties coupled with relatively reduced androgenic activity compared to testosterone. It exhibits strong binding to sex hormone-binding globulin (SHBG), which paradoxically can increase the free fraction of other concurrently administered steroids by displacing them from carrier proteins. The compound also appears to stimulate erythropoiesis-red blood cell production-quite potently, an effect that has been documented in both animal models and anecdotal human reports. This erythrogenic property was actually among the reasons for its veterinary utility, as improved oxygen-carrying capacity benefits equine athletic performance.

    Unlike many testosterone derivatives, boldenone does not undergo significant aromatization to estrogen via the aromatase enzyme. However, it is not entirely non-aromatizing; trace conversion can occur, and the compound itself possesses some inherent estrogenic activity, though substantially milder than testosterone. Similarly, its 5-alpha reduced metabolite appears to have minimal androgenic activity in most tissues, reducing concerns regarding androgenic side effects such as prostate enlargement and androgenic alopecia, though these risks are not entirely absent.

    The undecylenate ester creates one of the longest elimination half-lives among injectable steroid esters. Pharmacokinetic studies in veterinary contexts suggest the terminal half-life extends to approximately 14-16 days, though some sources cite ranges extending even longer depending on the assay methodology and species studied. This extended half-life results from the ester's high lipophilicity, slow hydrolysis by esterases, and subsequent prolonged release from adipose and muscle depots.

    The extended half-life carries significant clinical implications. Steady-state concentrations require several weeks to achieve, and complete elimination from the body following cessation can require months rather than weeks. This prolonged residence time affects endocrine recovery, detection windows in anti-doping screens, and the duration of potential adverse effects. The compound is metabolized primarily in the liver through phase I and phase II biotransformation pathways, with metabolites excreted through both renal and fecal routes.

    In veterinary settings, boldenone undecylenate produces reliable increases in lean tissue mass, improved nitrogen retention, and enhanced appetite-effects that translate from the fundamental anabolic properties of androgen receptor activation. The compound increases protein synthesis at the cellular level, upregulates myogenic signaling pathways, and promotes positive nitrogen balance. These mechanisms are not unique to boldenone but represent the shared anabolic activity of all AAS compounds.

    The erythropoietic effects deserve particular mention. Boldenone appears to stimulate erythropoietin production or enhance bone marrow sensitivity to erythropoietin, resulting in increased hematocrit and hemoglobin levels. While this might theoretically enhance endurance through improved oxygen delivery, it also elevates risks of polycythemia, increased blood viscosity, and thromboembolic events. Several case reports in the medical literature document severe polycythemia in individuals using boldenone, sometimes requiring therapeutic phlebotomy.

    The use of boldenone undecylenate in humans-particularly at supraphysiological doses and in unregulated underground preparations-carries substantial health risks. Cardiovascular toxicity represents perhaps the most significant concern. AAS use in general correlates with adverse lipid profile changes: reductions in high-density lipoprotein (HDL), increases in low-density lipoprotein (LDL), and elevated triglycerides. Boldenone specifically appears to suppress HDL cholesterol quite potently, accelerating atherosclerotic risk. Combined with the aforementioned polycythemia, the cardiovascular risk profile becomes particularly concerning.

    Hepatic effects, while less pronounced than with 17-alpha alkylated oral steroids, still warrant consideration. Although boldenone is not C17-alpha alkylated and thus avoids the direct hepatotoxicity associated with compounds like methyltestosterone or stanozolol, any exogenous steroid can affect hepatic protein synthesis, coagulation factor production, and lipid metabolism. Injectable routes reduce but do not eliminate hepatic strain.

Endocrine disruption follows predictable patterns. Exogenous androgen administration suppresses the hypothalamic-pituitary-gonadal axis through negative feedback, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. This suppression leads to testicular atrophy, impaired spermatogenesis, and hypogonadism that can persist long after discontinuation. The recovery of endogenous testosterone production following boldenone cessation is complicated by its extended half-life; the compound remains suppressive for weeks or months after the final injection, prolonging the hypogonadal state.

    Dermatological and cosmetic effects include acne vulgaris, seborrhea, and in susceptible individuals, androgenetic alopecia. Virilization in female users is a significant risk given the compound's androgenic activity, though it may be somewhat less virilizing than testosterone or more androgenic compounds. Voice deepening, hirsutism, clitoral enlargement, and menstrual irregularities represent potential outcomes.

    Psychiatric effects associated with AAS use broadly include mood disturbances, irritability, aggression, and in vulnerable individuals, more severe psychiatric sequelae. Whether boldenone carries unique neuropsychiatric risks compared to other AAS remains unclear, but it would be subject to the same general risks of androgenic modulation of central nervous system function.

Brand	STROMUSC
Trade names	Boldane, Equipoise, Parenabol, Vebonol
CAS	13103-34-9
Molar mass	452.679
Formula	C30H44O3
Purity	Above 98%
Capacity/Bottle	600mg/ml,10ml/bottle

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                  

 

    Boldenone undecylenate occupies a unique niche in pharmacological history as a veterinary anabolic agent that crossed into human use through the underground economy of performance enhancement. Its structural modifications produce a compound with prolonged activity, moderate anabolic effects, and distinct metabolic characteristics.

Hot Tags: high-quality stromusc boldane(boldenolone undecylenate)600mg/ml for bodybuilding cas:13103-34-9, China high-quality stromusc boldane(boldenolone undecylenate)600mg/ml for bodybuilding cas:13103-34-9 manufacturers, suppliers, factory